Join
Live feed
·
PRReleasevia Quantisnow
EQRx Inc. logo

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

ByQuantisnow·Wall Street's wire, on your screen.
EQRX· EQRx Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EQRX (EQRx Inc.) and more on Quantisnow.